Literature DB >> 16309183

Clinical significance of double staining of MIB-1 and AgNORs in primary breast carcinoma.

Hideo Kidogawa1, Atsushi Nanashima, Hiroshi Yano, Megumi Matsumoto, Toru Yasutake, Takeshi Nagayasu.   

Abstract

BACKGROUND: Argyrophilic nucleolar organizer regions (AgNORs) and MIB-1 as proliferating activities have been applied separately to assess the malignant potential of cancer cells. We conducted staining of AgNORs and MIB-1 in 42 surgically-resected invasive breast carcinomas.
MATERIALS AND METHODS: Paraffin-embedded sections were used for double staining and the mean AgNOR counts in 100 MIB-1-positive and -negative cells were calculated.
RESULTS: The mean AgNOR count in MIB-1-positive cells was significantly higher than in MIB-1-negative ones. AgNOR counts in MIB-1-positive tumors were significantly higher in tumors > or =2 cm and those with positive nodes. Multivariate analysis identified the AgNOR count in MIB-1-positive tumors as the only independent factor related to node metastasis. Survival of patients with lower counts of AgNORs in MIB-1-positive tumors was significantly better compared to those with higher counts.
CONCLUSION: Double staining of MIB-1 and AgNORs is useful for predicting lymph node metastasis and prognosis of patients with breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309183

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Histopathological study comparing upstream binding factor expression and AgNOR staining.

Authors:  A Torres-Montaner; M Huq
Journal:  Cell Prolif       Date:  2012-08       Impact factor: 6.831

2.  Argyrophilic nucleolar organizer region in MIB-1 positive cells in non-small cell lung cancer: clinicopathological significance and survival.

Authors:  Dmitriy Sergeevich Kobyakov; Ashot Merudzhanovich Avdalyan; Aleksandr Fedorovich Lazarev; Elena Leonidovna Lushnikova; Lev Moiseevich Nepomnyashchikh
Journal:  Cancer Biol Med       Date:  2014-12       Impact factor: 4.248

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.